ADCYAP1 and migraine disorder: On the other hand, since PACAP38 exerts its activity on other receptors in addition to PAC1, it cannot be excluded that monoclonal antibodies targeting the PACAP ligand may be more beneficial as a migraine preventive strategy, and there are anti-PACAP monoclonal antibodies targeting the ligand under development (i.e., LY 3451838, Lu AG09222) to date [47].